243 related articles for article (PubMed ID: 11468231)
1. Discrimination of prostate cancer from benign disease by plasma measurement of intact, free prostate-specific antigen lacking an internal cleavage site at Lys145-Lys146.
Nurmikko P; Pettersson K; Piironen T; Hugosson J; Lilja H
Clin Chem; 2001 Aug; 47(8):1415-23. PubMed ID: 11468231
[TBL] [Abstract][Full Text] [Related]
2. Dual-label immunoassay for simultaneous measurement of prostate-specific antigen (PSA)-alpha1-antichymotrypsin complex together with free or total PSA.
Zhu L; Leinonen J; Zhang WM; Finne P; Stenman UH
Clin Chem; 2003 Jan; 49(1):97-103. PubMed ID: 12507965
[TBL] [Abstract][Full Text] [Related]
3. Generation of PSA-ACT-specific monoclonal antibodies and their application in a sandwich immunoassay.
Wang TJ; Linton HJ; Payne J; Rittenhouse HG; Chan DW; Partin AW; Wolfert RL; Kuus-Reichel K
Hybridoma; 1999 Dec; 18(6):535-41. PubMed ID: 10626683
[TBL] [Abstract][Full Text] [Related]
4. Ratio of free or complexed prostate-specific antigen (PSA) to total PSA: which ratio improves differentiation between benign prostatic hyperplasia and prostate cancer?
Jung K; Elgeti U; Lein M; Brux B; Sinha P; Rudolph B; Hauptmann S; Schnorr D; Loening SA
Clin Chem; 2000 Jan; 46(1):55-62. PubMed ID: 10620572
[TBL] [Abstract][Full Text] [Related]
5. Determination of non-alpha1-antichymotrypsin-complexed prostate-specific antigen as an indirect measurement of free prostate-specific antigen: analytical performance and diagnostic accuracy.
Wesseling S; Stephan C; Semjonow A; Lein M; Brux B; Sinha P; Loening SA; Jung K
Clin Chem; 2003 Jun; 49(6 Pt 1):887-94. PubMed ID: 12765984
[TBL] [Abstract][Full Text] [Related]
6. Determination of alpha1-antichymotrypsin-PSA complex in serum does not improve the differentiation between benign prostatic hyperplasia and prostate cancer compared with total PSA and percent free PSA.
Jung K; Brux B; Lein M; Knäbich A; Sinha P; Rudolph B; Schnorr D; Loening SA
Urology; 1999 Jun; 53(6):1160-7; discussion 1167-8. PubMed ID: 10367846
[TBL] [Abstract][Full Text] [Related]
7. Enhanced discrimination of benign from malignant prostatic disease by selective measurements of cleaved forms of urokinase receptor in serum.
Piironen T; Haese A; Huland H; Steuber T; Christensen IJ; Brünner N; Danø K; Høyer-Hansen G; Lilja H
Clin Chem; 2006 May; 52(5):838-44. PubMed ID: 16543389
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the clinical validity of free prostate-specific antigen, alpha-1 antichymotrypsin-bound prostate-specific antigen and complexed prostate-specific antigen in prostate cancer diagnosis.
Lein M; Jung K; Elgeti U; Petras T; Stephan C; Brux B; Sinha P; Winkelmann B; Schnorr D; Loening S
Eur Urol; 2001 Jan; 39(1):57-64. PubMed ID: 11173940
[TBL] [Abstract][Full Text] [Related]
9. A multicenter clinical trial on the use of alpha1-antichymotrypsin-prostate-specific antigen in prostate cancer diagnosis.
Lein M; Jung K; Hammerer P; Graefen M; Semjonow A; Stieber P; Ossendorf M; Luboldt HJ; Brux B; Stephan C; Schnorr D; Loening SA
Prostate; 2001 May; 47(2):77-84. PubMed ID: 11340629
[TBL] [Abstract][Full Text] [Related]
10. Discrimination of benign from malignant prostatic disease by selective measurements of single chain, intact free prostate specific antigen.
Steuber T; Nurmikko P; Haese A; Pettersson K; Graefen M; Hammerer P; Huland H; Lilja H
J Urol; 2002 Nov; 168(5):1917-22. PubMed ID: 12394676
[TBL] [Abstract][Full Text] [Related]
11. Human Kallikrein-2, Prostate Specific Antigen and Free- Prostate Specific Antigen in Combination to Discriminate Prostate Cancer from Benign Diseases in Syrian Patients.
Bachour DM; Chahin E; Al-Fahoum S
Asian Pac J Cancer Prev; 2015; 16(16):7085-8. PubMed ID: 26514494
[TBL] [Abstract][Full Text] [Related]
12. Proximity ligation measurement of the complex between prostate specific antigen and alpha1-protease inhibitor.
Zhu L; Koistinen H; Landegren U; Stenman UH
Clin Chem; 2009 Sep; 55(9):1665-71. PubMed ID: 19643837
[TBL] [Abstract][Full Text] [Related]
13. Determination of prostate-specific antigen complexed to alpha(2)-macroglobulin in serum increases the specificity of free to total PSA for prostate cancer.
Zhang WM; Finne P; Leinonen J; Salo J; Stenman UH
Urology; 2000 Aug; 56(2):267-72. PubMed ID: 10925092
[TBL] [Abstract][Full Text] [Related]
14. Contemporary use of complexed PSA and calculated percent free PSA for early detection of prostate cancer: impact of changing disease demographics.
Miller MC; O'Dowd GJ; Partin AW; Veltri RW
Urology; 2001 Jun; 57(6):1105-11. PubMed ID: 11377319
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of proprostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0 to 10.0 ng/ml.
Khan MA; Partin AW; Rittenhouse HG; Mikolajczyk SD; Sokoll LJ; Chan DW; Veltri RW
J Urol; 2003 Sep; 170(3):723-6. PubMed ID: 12913682
[TBL] [Abstract][Full Text] [Related]
16. Analysis of subforms of free prostate-specific antigen in serum by two-dimensional gel electrophoresis: potential to improve diagnosis of prostate cancer.
Jung K; Reiche J; Boehme A; Stephan C; Loening SA; Schnorr D; Hoesel W; Sinha P
Clin Chem; 2004 Dec; 50(12):2292-301. PubMed ID: 15472031
[TBL] [Abstract][Full Text] [Related]
17. Value of the free to total prostate specific antigen ratio and prostate specific antigen density for detecting prostate cancer in Japanese patients.
Maeda H; Arai Y; Okubo K; Aoki Y; Okada T; Maekawa S
Int J Urol; 1998 Jul; 5(4):343-8. PubMed ID: 9712442
[TBL] [Abstract][Full Text] [Related]
18. Molecular forms of prostate-specific antigen in serum with concentrations of total prostate-specific antigen <4 microg/L: are they useful tools for early detection and screening of prostate cancer?
Jung K; Stephan C; Elgeti U; Lein M; Brux B; Kristiansen G; Rudolph B; Hauptmann S; Schnorr D; Loening SA; Sinha P
Int J Cancer; 2001 Sep; 93(5):759-65. PubMed ID: 11477592
[TBL] [Abstract][Full Text] [Related]
19. Total PSA, free PSA/total PSA ratio, and molecular PSA detection in prostate cancer: which is clinically effective and when?
Basso D; Fogar P; Piva MG; Navaglia F; Mazza S; Prayer-Galetti T; Castellucci E; Pagano F; Plebani M
Urology; 2000 May; 55(5):710-5. PubMed ID: 10792086
[TBL] [Abstract][Full Text] [Related]
20. Immunoassay for the discrimination of free prostate-specific antigen (fPSA) forms with internal cleavages at Lys(₁₄₅) or Lys(₁₄₆) from fPSA without internal cleavages at Lys(₁₄₅) or Lys(₁₄₆).
Peltola MT; Niemelä P; Alanen K; Nurmi M; Lilja H; Pettersson K
J Immunol Methods; 2011 Jun; 369(1-2):74-80. PubMed ID: 21554885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
